MCID: MCC002
MIFTS: 47

Mucocutaneous Leishmaniasis malady

Categories: Infectious diseases

Aliases & Classifications for Mucocutaneous Leishmaniasis

Aliases & Descriptions for Mucocutaneous Leishmaniasis:

Name: Mucocutaneous Leishmaniasis 12 14 69
American Cutaneous Leishmaniasis 12 69
Mucocutaneous Leishmaniasis, American 12
American Mucocutaneous Leishmaniasis 12
Cutaneous Leishmaniasis, American 12
New World Cutaneous Leishmaniasis 12
Mucocutaneous Leishmaniasis, 12
Leishmaniasis, Mucocutaneous 42

Classifications:



External Ids:

Disease Ontology 12 DOID:9155
ICD10 33 B55.2
ICD9CM 35 085.5
MeSH 42 D007897
UMLS 69 C1328252

Summaries for Mucocutaneous Leishmaniasis

Disease Ontology : 12 A leishmaniasis that involves a chronic inflammatory process involving the nasal, pharyngeal, and laryngeal mucosa, which can lead to extensive tissue destruction, caused by protozoan parasites belonging to the genus Leishmania. The infection is characterized by granulomatous lesion which can destroy upper respiratory tract mucosa.

MalaCards based summary : Mucocutaneous Leishmaniasis, also known as american cutaneous leishmaniasis, is related to leishmaniasis and pyridoxal 5'-phosphate-dependent epilepsy. An important gene associated with Mucocutaneous Leishmaniasis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Miconazole and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and skin, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Related Diseases for Mucocutaneous Leishmaniasis

Diseases related to Mucocutaneous Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
id Related Disease Score Top Affiliating Genes
1 leishmaniasis 10.8
2 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
3 multiple vertebral anomalies unusual facies 10.3 IL10 TNF
4 endosalpingiosis 10.3 IL10 TNF
5 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.3 IL10 TNF
6 tarsal tunnel syndrome 10.3 IL10 TNF
7 chronic apical periodontitis 10.2 IL10 TNF
8 plantar wart 10.2 IL10 TNF
9 spondylometaphyseal dysplasia east-african type 10.2 LTA TNF
10 thymic neuroendocrine carcinoma 10.2 LTA TNF
11 prostate calculus 10.2 CD4 TNF
12 inflammatory breast carcinoma 10.2 IL10 LTA
13 parkinson disease 11 10.2 IL10 TNF
14 dermatitis herpetiformis 10.2 CD4 TNF
15 drug dependence 10.2 LTA TNF
16 kernicterus due to isoimmunization 10.2 LTA TNF
17 facial paralysis 10.2 CD4 IL10
18 autosomal dominant deafness-onychodystrophy syndrome 10.2 IL4 TNF
19 asymptomatic neurosyphilis 10.2 IL10 IL4
20 ciliary discoordination, due to random ciliary orientation 10.2 CD4 IL10
21 ceroid lipofuscinosis, neuronal, 3 10.2 IL10 IL4
22 depressed scar 10.2 IL10 TLR3 TNF
23 tungiasis 10.2 IL10 IL4
24 urethral intrinsic sphincter deficiency 10.1 IL4 TNF
25 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.1 IL10 IL4
26 goat milk allergy 10.1 IL10 IL4
27 uveitis 10.1 CD4 TNF
28 indian plum allergy 10.1 IL10 IL4
29 centronuclear myopathy 5 10.1 IL10 IL4
30 abdominal tuberculosis 10.1 CD4 IL10
31 clostridium difficile colitis 10.1 IL4 TNF
32 kala-azar 1 10.1
33 steatitis 10.1 CD8A TNF
34 hypotrichosis 4 10.1 IL4 TNF
35 idiopathic hypertrophic pachymeningitis 10.1 IL10 LTA TNF
36 transient tic disorder 10.1 CD4 IL10 TNF
37 hypoparathyroidism-retardation-dysmorphism syndrome 10.1 CD4 IL10 TNF
38 sarcomatoid transitional cell carcinoma 10.1 CD4 IL10 TNF
39 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.1 CD4 IL10 TNF
40 primary ciliary dyskinesia 10.1 IL10 LTA TNF
41 cryptococcosis 10.1 CD4 IL10 TNF
42 hyperoxaluria, primary, type ii 10.1 CD8A TNF
43 anterior foramen magnum meningioma 10.1 CD4 IL10 TNF
44 anus leiomyosarcoma 10.1 CD4 IL10 TNF
45 detrusor sphincter dyssynergia 10.1 CD4 IL10 TNF
46 eczematous dermatitis of eyelid 10.1 IL10 TLR3 TNF
47 anterior dislocation of lens 10.1 CD4 IL4
48 lens-induced iridocyclitis 10.1 CD4 IL4
49 paralytic poliomyelitis 10.1 CD8A TLR3
50 cauda equina syndrome 10.1 LTA TNF

Graphical network of the top 20 diseases related to Mucocutaneous Leishmaniasis:



Diseases related to Mucocutaneous Leishmaniasis

Symptoms & Phenotypes for Mucocutaneous Leishmaniasis

MGI Mouse Phenotypes related to Mucocutaneous Leishmaniasis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.01 TLR3 TNF CD4 CD8A IL10 IL4
2 endocrine/exocrine gland MP:0005379 9.98 CD4 CD8A IL10 IL4 LTA TLR3
3 immune system MP:0005387 9.97 CD4 CD8A IL10 IL4 LTA SCYL1
4 cardiovascular system MP:0005385 9.93 IL10 LTA NID1 SCYL1 TLR3 TNF
5 mortality/aging MP:0010768 9.92 TLR3 TNF CD4 CD8A IL10 IL4
6 nervous system MP:0003631 9.81 CD4 CD8A IL10 IL4 LTA NID1
7 muscle MP:0005369 9.65 IL10 NID1 SCYL1 TLR3 TNF
8 respiratory system MP:0005388 9.35 IL10 IL4 LTA TLR3 TNF
9 vision/eye MP:0005391 9.1 IL10 IL4 LTA NID1 SCYL1 TNF

Drugs & Therapeutics for Mucocutaneous Leishmaniasis

Drugs for Mucocutaneous Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
2
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
3
Pentamidine Approved Phase 2, Phase 3 100-33-4 4735
4
Paromomycin Approved, Investigational Phase 2, Phase 3 1263-89-4, 7542-37-2 165580
5 meglumine antimoniate Phase 2, Phase 3
6 Anti-Infective Agents Phase 2, Phase 3, Phase 1
7 Antifungal Agents Phase 2, Phase 3,Phase 1
8 Antiparasitic Agents Phase 2, Phase 3, Phase 1
9 Antiprotozoal Agents Phase 2, Phase 3, Phase 1
10 Anti-Bacterial Agents Phase 2, Phase 3
11
Amphotericin B Approved, Investigational Phase 1, Phase 2 1397-89-3 14956 5280965
12
Miltefosine Approved Phase 2,Phase 1 58066-85-6 3600
13
Coal tar Approved Phase 2 8007-45-2
14
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
15 Anthelmintics Phase 1, Phase 2
16 Liposomal amphotericin B Phase 1, Phase 2
17 Antimony Sodium Gluconate Phase 1, Phase 2
18 Vasodilator Agents Phase 2
19 Phosphodiesterase Inhibitors Phase 2
20 Platelet Aggregation Inhibitors Phase 2
21 Protective Agents Phase 2
22 Radiation-Protective Agents Phase 2
23 Antioxidants Phase 2
24 Vaccines Phase 1
25
Cortisone acetate Approved 1950-04-4, 50-04-4 5745
26
Cortisone 53-06-5 222786
27 Anti-Inflammatory Agents

Interventional clinical trials:

(show all 16)
id Name Status NCT ID Phase
1 Low Antimonial Dosage in American Mucosal Leishmaniasis Recruiting NCT01301937 Phase 2, Phase 3
2 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Not yet recruiting NCT03096457 Phase 2, Phase 3
3 Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis Completed NCT01377974 Phase 2
4 Miltefosine to Treat Mucocutaneous Leishmaniasis Completed NCT01050907 Phase 2
5 Miltefosine for Mucosal Leishmaniasis Completed NCT00373776 Phase 1, Phase 2
6 Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis Completed NCT00373568 Phase 1, Phase 2
7 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2
8 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2
9 Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia Completed NCT00233545 Phase 2
10 The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: A Clinical Trial in Brazil Recruiting NCT02530697 Phase 2
11 Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis Completed NCT00111514 Phase 1
12 Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis Recruiting NCT02429518
13 Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis Recruiting NCT02431429
14 Diagnosis and Treatment of Leishmanial Infections Recruiting NCT00344188
15 Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis Available NCT00508963
16 Cortisone and QTc-Interval Not yet recruiting NCT03082339

Search NIH Clinical Center for Mucocutaneous Leishmaniasis

Cochrane evidence based reviews: leishmaniasis, mucocutaneous

Genetic Tests for Mucocutaneous Leishmaniasis

Anatomical Context for Mucocutaneous Leishmaniasis

MalaCards organs/tissues related to Mucocutaneous Leishmaniasis:

39
T Cells, Testes, Skin, Monocytes

Publications for Mucocutaneous Leishmaniasis

Articles related to Mucocutaneous Leishmaniasis:

(show top 50) (show all 144)
id Title Authors Year
1
Mucocutaneous leishmaniasis. ( 26994882 )
2016
2
Mucocutaneous leishmaniasis with marked facial disfigurement. ( 27643545 )
2016
3
Unusual presentation of mucocutaneous leishmaniasis in HIV-infected patient. ( 27890957 )
2016
4
Mucocutaneous leishmaniasis must be included in the differential diagnosis of midline destructive disease: two case reports. ( 25442251 )
2015
5
Short communication: mucocutaneous leishmaniasis in HIV-related immune reconstitution syndrome. ( 26154873 )
2015
6
Mucocutaneous leishmaniasis in an 11-year-old girl with ataxia telangectasia - case report. ( 25661291 )
2015
7
Immune response to Leishmania antigens in an AIDS patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS): a case report. ( 25645330 )
2015
8
Mucocutaneous leishmaniasis of the nose: a case report. ( 26513953 )
2015
9
Accuracy of mucocutaneous leishmaniasis diagnosis using polymerase chain reaction: systematic literature review and meta-analysis. ( 25946238 )
2015
10
Mucocutaneous leishmaniasis caused by Leishmania infantum var Lombardi in an immunocompetent patient, Spain. ( 25559703 )
2015
11
Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives. ( 26568335 )
2015
12
Polymerase chain reaction-miniexon: a promising diagnostic method for mucocutaneous leishmaniasis. ( 26452681 )
2015
13
Accuracy of mucocutaneous leishmaniasis diagnosis using polymerase chain reaction: systematic literature review and meta-analysis. ( 25830540 )
2015
14
Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management. ( 26568336 )
2015
15
A case of mucocutaneous leishmaniasis diagnosed by serology. ( 25041360 )
2014
16
Mucocutaneous leishmaniasis as presentation of HIV infection in Sardinia, insular Italy. ( 24126182 )
2014
17
Ear, nose and throat manifestations of mucocutaneous Leishmaniasis: a literature review. ( 24897964 )
2014
18
Mucocutaneous Leishmaniasis/HIV Coinfection Presented as a Diffuse Desquamative Rash. ( 25548691 )
2014
19
Mucocutaneous leishmaniasis caused by Leishmania donovani infection in an Indian man. ( 25557311 )
2014
20
Mucocutaneous leishmaniasis: accuracy and molecular validation of noninvasive procedures in a L. (V.) braziliensis-endemic area. ( 24923211 )
2014
21
Mucocutaneous leishmaniasis: knowledge, attitudes, and practices among paraguayan communities, patients, and health professionals. ( 23690792 )
2013
22
Phosphatidylserine exposure and surface sugars in two Leishmania (Viannia) braziliensis strains involved in cutaneous and mucocutaneous leishmaniasis. ( 23148292 )
2013
23
Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis. ( 24170665 )
2013
24
Mucocutaneous leishmaniasis: mucosal manifestations in an endemic country. ( 23867693 )
2013
25
Cutaneous and mucocutaneous leishmaniasis resembling borderline-tuberculoid leprosy: a new clinical presentation? ( 22434112 )
2013
26
First molecular-based detection of mucocutaneous leishmaniasis caused by Leishmania major in Iran. ( 23669431 )
2013
27
Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. ( 23637917 )
2013
28
Accurate and rapid species typing from cutaneous and mucocutaneous leishmaniasis lesions of the New World. ( 22819605 )
2012
29
Cutaneous and mucocutaneous leishmaniasis. ( 22632640 )
2012
30
Primary lesion of mucocutaneous leishmaniasis simulating external otitis. ( 23108835 )
2012
31
Mucocutaneous leishmaniasis in a patient treated with anti-TNF-I+ therapy. ( 22427411 )
2012
32
Polymerase chain reaction detection of Leishmania kDNA from the urine of Peruvian patients with cutaneous and mucocutaneous leishmaniasis. ( 21460009 )
2011
33
Mucocutaneous Leishmaniasis: clinical markers in presumptive diagnosis. ( 21739015 )
2011
34
Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. ( 21311023 )
2011
35
Diffuse mucocutaneous leishmaniasis. ( 22479746 )
2011
36
Treatment strategies for mucocutaneous leishmaniasis. ( 20606970 )
2010
37
Comment on: Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns. ( 19836815 )
2010
38
Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. ( 20377337 )
2010
39
Mucocutaneous leishmaniasis masquerading as Wegener granulomatosis. ( 20375822 )
2010
40
Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management. ( 20163267 )
2010
41
A chronic mutilating rhinopathy with a delayed diagnosis of mucocutaneous leishmaniasis. ( 20465699 )
2010
42
Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns. ( 19356780 )
2009
43
Interventions for American cutaneous and mucocutaneous leishmaniasis. ( 19370612 )
2009
44
The value of the otorhinolaryngologic exam in correct mucocutaneous leishmaniasis diagnosis. ( 19706900 )
2009
45
Cutaneous and mucocutaneous leishmaniasis. ( 19889134 )
2009
46
Successful diagnosis and treatment 50 years after exposure: is mucocutaneous leishmaniasis still a neglected differential diagnosis? ( 19090806 )
2008
47
Cytokine profile in Montenegro skin test of patients with localized cutaneous and mucocutaneous leishmaniasis. ( 19082374 )
2008
48
Mucocutaneous leishmaniasis treated with liposomal amphotericin B. ( 18368279 )
2008
49
Enhancement of a TH1 immune response in amphotericin B-treated mucocutaneous leishmaniasis. ( 17641726 )
2007
50
Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. ( 17556623 )
2007

Variations for Mucocutaneous Leishmaniasis

Expression for Mucocutaneous Leishmaniasis

Search GEO for disease gene expression data for Mucocutaneous Leishmaniasis.

Pathways for Mucocutaneous Leishmaniasis

Pathways related to Mucocutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 CD4 IL10 IL4 LTA TLR3 TNF
2
Show member pathways
13.14 CD4 IL10 IL4 LTA TNF
3
Show member pathways
13.08 CD4 IL10 IL4 LTA TNF
4
Show member pathways
12.6 IL4 LTA TLR3 TNF
5
Show member pathways
12.54 CD4 CD8A IL10 IL4 LTA TNF
6
Show member pathways
12.46 CD4 IL10 IL4 TNF
7
Show member pathways
12.41 CD4 IL10 IL4 TNF
8 12.37 CD8A IL10 IL4 TLR3 TNF
9
Show member pathways
12.24 CD4 CD8A IL10 IL4 TNF
10
Show member pathways
12.07 IL10 IL4 TNF
11
Show member pathways
12.02 IL10 IL4 LTA TNF
12 11.83 IL10 IL4 TNF
13
Show member pathways
11.82 CD4 CD8A IL4
14
Show member pathways
11.77 CD4 IL4 TLR3
15 11.74 CD4 CD8A IL4 TNF
16 11.72 CD4 CD8A IL10 IL4 TNF
17 11.59 CD4 CD8A IL10 TNF
18 11.53 IL10 IL4 LTA
19 11.51 IL10 IL4 LTA TNF
20 11.41 IL10 IL4 TNF
21 11.38 CD4 IL10 IL4
22
Show member pathways
11.38 CD4 IL10 LTA TLR3 TNF
23 11.21 CD4 CD8A
24 11.19 IL10 TNF
25 11.18 IL10 TNF
26 11.14 IL4 TNF
27 11.09 IL10 IL4 LTA
28 11.06 IL10 IL4 LTA TNF
29 11 CD4 CD8A IL10 IL4 LTA TNF
30 10.93 CD4 IL10 IL4 TNF

GO Terms for Mucocutaneous Leishmaniasis

Cellular components related to Mucocutaneous Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 CD8A IL10 IL4 LTA NID1 TNF
2 cell surface GO:0009986 9.46 CD4 CD8A TLR3 TNF
3 T cell receptor complex GO:0042101 8.96 CD4 CD8A
4 external side of plasma membrane GO:0009897 8.92 CD4 CD8A IL4 TNF

Biological processes related to Mucocutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show all 33)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.94 CD4 IL10 IL4 TNF
2 defense response to bacterium GO:0042742 9.83 IL10 TLR3 TNF
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.79 CD4 TLR3 TNF
4 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.72 IL10 IL4 TNF
5 positive regulation of cytokine secretion GO:0050715 9.65 IL10 TNF
6 negative regulation of endothelial cell apoptotic process GO:2000352 9.65 IL10 IL4
7 positive regulation of cytokine production GO:0001819 9.65 TLR3 TNF
8 negative regulation of mitotic cell cycle GO:0045930 9.64 IL10 TNF
9 positive regulation of interleukin-8 production GO:0032757 9.63 TLR3 TNF
10 negative regulation of interleukin-6 production GO:0032715 9.63 IL10 TNF
11 negative regulation of osteoclast differentiation GO:0045671 9.62 IL4 TLR3
12 positive regulation of NF-kappaB import into nucleus GO:0042346 9.62 TLR3 TNF
13 defense response to protozoan GO:0042832 9.61 IL10 IL4
14 positive regulation of calcium-mediated signaling GO:0050850 9.6 CD4 CD8A
15 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.59 IL10 TNF
16 positive regulation of chemokine production GO:0032722 9.58 TLR3 TNF
17 microglial cell activation GO:0001774 9.58 IL4 TLR3
18 negative regulation of nitric oxide biosynthetic process GO:0045019 9.57 IL10 IL4
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.56 IL10 TNF
20 positive regulation of protein phosphorylation GO:0001934 9.56 CD4 IL4 TLR3 TNF
21 endothelial cell apoptotic process GO:0072577 9.54 IL10 TNF
22 positive regulation of MHC class II biosynthetic process GO:0045348 9.52 IL10 IL4
23 necroptotic signaling pathway GO:0097527 9.51 TLR3 TNF
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.49 IL10 TNF
25 type 2 immune response GO:0042092 9.48 IL10 IL4
26 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.46 LTA TNF
27 regulation of isotype switching GO:0045191 9.43 IL10 IL4
28 immune response GO:0006955 9.43 CD4 CD8A IL10 IL4 LTA TNF
29 positive regulation of mononuclear cell migration GO:0071677 9.4 IL4 TNF
30 receptor biosynthetic process GO:0032800 9.37 IL10 TNF
31 negative regulation of growth of symbiont in host GO:0044130 9.33 IL10 LTA TNF
32 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.32 LTA TNF
33 positive regulation of chemokine biosynthetic process GO:0045080 8.8 IL4 TLR3 TNF

Molecular functions related to Mucocutaneous Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.16 LTA TNF
2 coreceptor activity GO:0015026 8.96 CD4 CD8A
3 cytokine activity GO:0005125 8.92 IL10 IL4 LTA TNF

Sources for Mucocutaneous Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....